Intarcia Archives

numab intarcia antibodies implantable drug delivery

News and Trends 6 Jun 2016

Swiss-US Implant could make taking pills obsolete in Autoimmune Diseases

Numab and Intarcia have achieved key milestones in the development of therapeutic antibody fragments. This collaboration could span the next generation of implantable drug delivery tech for diabetes, obesity and…

June 6, 2016 - 2 minutesmins - By Denise Neves Gameiro

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching 'epidemic proportions', we figured it was time to have a better overview of biotech's progress in the field. With some serious advances having been…

June 14, 2016 - 9 minutesmins - By Dani Bancroft

News and Trends 23 Feb 2018

Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes

Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment…

February 23, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 15 Sep 2017

Swiss-US Partners Reveal New Candidate for Autoimmune Disease

Numab and Intarcia have a first candidate to combine a tri-specific antibody fragment with a mini-osmotic pump delivery system to fight autoimmune disease. Numab and Intarcia partnered in 2015 to…

September 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Jan 2017

Fresh Cash for a Device that Can Treat Diabetes and Prevent HIV

Intarcia will develop a drug delivery device for HIV prevention that can significantly reduce dosing frequency, backed by a €134M ($140M) deal with the Bill & Melinda Gates Foundation. Intarcia…

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn't changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech…

September 18, 2015 - 3 minutesmins - By Philip Hemme

future biomarkers immuno oncology lymphocytes

News and Trends 31 Aug 2015

Review: The Future of Biomarkers in Immuno-Oncology

Immuno-oncology is a Biotech field that is more than just hype - it could solve one of humanity's biggest health challenges: Cancer. [caption id="attachment_10346" align="alignright" width="272"] Bernhard Sixt, CEO of…

August 31, 2015 - 5 minutesmins - By Philip Hemme

Intarcia Platform Technology deal Servier

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first…

November 15, 2014 - 2 minutesmins - By Julie Lellouche

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering